Audio Journal of Oncology in Advance – November 15th, 2006

REFERENCE: Chemotherapy Foundation Symposium XXIV 8-11 November 2006
DANIEL PETRYLAK, Columbia Presbyterian Medical Center, New York
COMMENT: EDWARD AMBINDER, Mount Sinai School of Medicine, New York
In hormone refractory prostate cancer, chemotherapy and immunotherapy can work together – and the next task is to work out how best to combine them. Daniel Petrylak of the Columbia Presbyterian Medical Center in New York had the details.

REFERENCE: Chemotherapy Foundation Symposium XXIV 8-11 November 2006
OLIVER SARTOR, Dana-Farber Cancer Institute, Boston
COMMENT: EDWARD AMBINDER, Mount Sinai School of Medicine, New York
According to Oliver Sartor of the Dana-Farber Cancer Institute in Boston, the platinum agent satraplatin is a possible new treatment for androgen-independent prostate cancer.

REFERENCE: Chemotherapy Foundation Symposium XXIV 8-11 November 2006
MARK SOCINSKI, University of North Carolina, Chapel Hill
Paclitaxel linked to a polyglutamate backbone could work better in women – but some new evidence has raised concerns for investigators. Mark Socinski of the University of North Carolina in Chapel Hill shared the data in New York.

REFERENCE: Chemotherapy Foundation Symposium XXIV 8-11 November 2006
KANTI RAI, Long Island Jewish Medical Center, New York
COMMENT: EDWARD AMBINDER, Mount Sinai School of Medicine, New York
Kanti Rai of the Long Island Jewish Medical Center in New York has had encouraging results from adding the antisense molecule Genasense to chemotherapy, in patients with relapsed or refractory CLL.